Celsius Holdings Inc (NASDAQ:CELH) shares are trading lower Monday. Roth MKM analyst Sean McGowan maintained Celsius Holdings with a Buy rating on Monday, but cut the firm's price target from $96 to $87.
Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hypertension. Despite being well tolerated, AV-101 failed to meet primary and secondary endpoints. Enrollment for Phase 3 is halted.